Evidence map›Paper›PMID 33310057›Full record

ArticleExperimental eye research2021

Optimal timing for activation of sigma 1 receptor in the Pde6b

Jing Wang, Haiyan Xiao, Shannon Barwick, Yutao Liu, Sylvia B Smith

Open access · greenAbstract read
In one paragraph

Article in Experimental eye research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Molecular therapy. Nucleic acids · 2023
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jing WangDepartment of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, United States; James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, United States.
Haiyan XiaoDepartment of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, United States; James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, United States.
Shannon BarwickDepartment of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, United States; James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, United States.
Yutao LiuDepartment of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, United States; James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, United States.
Sylvia B SmithDepartment of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, United States; James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, United States; Department of Ophthalmology, Medical College of Georgia at Augusta University, Augusta, GA, United States. Electronic address: sbsmith@augusta.edu.
Augusta University · US

Funding

Module 3: Gene Expression/ProteomicsP30EY031631 · NEI · AUGUSTA UNIVERSITY · PI Xingjun Fan · 2020 to 2026
$3.6M
Gene Discovery in Familial KeratoconusR01EY023242 · NEI · DUKE UNIVERSITY · PI LIU, YUTAO · 2013 to 2023
$3.4M
Sigma 1 Receptor: a novel therapeutic target for retinal degenerationR01EY028103 · NEI · AUGUSTA UNIVERSITY · PI SMITH, SYLVIA B. · 2017 to 2019
$1.2M
Long Noncoding RNA lncLOXL1 and Exfoliation Syndrome.R21EY028671 · NEI · AUGUSTA UNIVERSITY · PI LIU, YUTAO · 2018 to 2019
$467k
NEI NIH HHS P30 EY031631NEI NIH HHS R01 EY023242NEI NIH HHS R01 EY028103NEI NIH HHS R21 EY028671
6 · The paper itself

Abstract

Sigma 1 Receptor (Sig1R), a pluripotent modulator of cell survival, is a promising target for treatment of retinal degenerative diseases. Previously, we reported that administration of the high-affinity, high-specificity Sig1R ligand (+)-pentazocine, ((+)-PTZ) beginning at post-natal day 14 (P14) and continuing every other day improves visual acuity and delays loss of photoreceptor cells (PRCs) in the Pde6βrd10/J (rd10) mouse model of retinitis pigmentosa. Whether administration of (+)-PTZ, at time points concomitant with (P18) or following (P21, P24) onset of PRC death, would prove neuroprotective was investigated in this study. Rd10 mice were administered (+)-PTZ intraperitoneally [0.5 mg/kg], starting at either P14, P18, P21 or P24. Injections continued every other day through P42. Visual acuity was assessed using the optokinetic tracking response (OKR). Rd10 mice treated with (+)-PTZ beginning at P14 retained visual acuity for the duration of the study (~0.33 c/d at P21, ~0.38 c/d at P28, ~0.32 c/d at P35, ~0.32 c/d at P42), whereas mice injected beginning at P18, P21, P24 showed a decline in acuity when tested at P35 and P42. Their acuity was only slightly better than rd10-non-treated mice. Electrophysiologic function was assessed using scotopic and photopic electroretinography (ERG) to assess rod and cone function, respectively. Photopic a- and b-wave amplitudes were significantly greater in rd10 mice treated with (+)-PTZ beginning at P14 compared with non-treated mice and those in the later-onset (+)-PTZ injection groups. Retinal architecture was visualized in living mice using spectral domain-optical coherence tomography (SD-OCT) allowing measurement of the total retinal thickness, the inner retina and the outer retina (the area most affected in rd10 mice). The outer retina measured ~35 μm in rd10 mice treated with (+)-PTZ beginning at P14, which was significantly greater than mice in the later-onset (+)-PTZ injection groups (~25 μm) and non-treated rd10 mice (~25 μm). Following the visual function studies performed in the living mice, eyes were harvested at P42 for histologic analysis. While the inner retina was largely intact in all (+)-PTZ-injection groups, there was a marked reduction in the outer retina of non-treated rd10 mice (e.g. in the outer nuclear layer there were ~10 PRCs/100 μm retinal length). The rd10 mice treated with (+)-PTZ beginning at P14 had ~20 PRCs/100 μm retinal length, whereas the mice in groups beginning P18, P21 and P24 had ~16 PRCs/100 μm retinal length. In conclusion, the data indicate that delaying (+)-PTZ injection past the onset of PRC death in rd10 mice - even by a few days - can negatively impact the long-term preservation of retinal function. Our findings suggest that optimizing the administration of Sig1R ligands is critical for retinal neuroprotection.

Indexed as

AnimalsCyclic Nucleotide Phosphodiesterases, Type 6Disease Models, AnimalElectroretinographyMiceMice, Inbred C57BLReceptors, sigmaRetinal Cone Photoreceptor CellsRetinal Rod Photoreceptor CellsRetinitis PigmentosaSigma-1 ReceptorTomography, Optical CoherenceCyclic Nucleotide Phosphodiesterases, Type 6Pde6b protein, mouseReceptors, sigmaSigma-1 ReceptorERGOCToptomotryPentazocinerd10 mouseRetinal degenerationRetinitis pigmentosaSigma 1 receptor

Identifiers

PMID33310057
PMCPMC7808329
OpenAlexW3112624709

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.